Kamada Ltd. (KMDA)
8.42
+0.18
(+2.18%)
USD |
NASDAQ |
Aug 24, 16:00
8.42
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 485.79M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 20.53% |
| Valuation | |
| PE Ratio | 22.06 |
| PE Ratio (Forward) | |
| PS Ratio | 2.578 |
| Price to Book Value | 1.802 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | 0.17 |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.0438 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 67.69% |
Profile
| Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment refers to specialty plasma therapies and normal source plasma ("NSP"). The Distribution segment focuses on the commercialization of in-licensed third-party biopharmaceutical products. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel. |
| URL | http://www.kamada.com |
| Investor Relations URL | https://www.kamada.com/financial-reports/ |
| HQ State/Province | HaMerkaz |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Core |
| Next Earnings Release | Nov. 09, 2026 (est.) |
| Last Earnings Release | Aug. 12, 2026 |
| Next Ex-Dividend Date | Aug. 27, 2026 |
| Last Ex-Dividend Date | Mar. 23, 2026 |
Profile
| Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment refers to specialty plasma therapies and normal source plasma ("NSP"). The Distribution segment focuses on the commercialization of in-licensed third-party biopharmaceutical products. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel. |
| URL | http://www.kamada.com |
| Investor Relations URL | https://www.kamada.com/financial-reports/ |
| HQ State/Province | HaMerkaz |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Core |
| Next Earnings Release | Nov. 09, 2026 (est.) |
| Last Earnings Release | Aug. 12, 2026 |
| Next Ex-Dividend Date | Aug. 27, 2026 |
| Last Ex-Dividend Date | Mar. 23, 2026 |